The overall prevalence of RET fusions is 1% to 2% in an unselected population of NSCLCs, however, this incidence increases substantially to 6% in never-smokers with lung adenocarcinomas that are pan-negative for other known driver mutations[13]. This evidence concerns the gene RET and lung adenocarcinoma.